MX2017005848A - Composicion farmaceutica que comprende un betabloqueante y un inhibidor de la enzima de conversion. - Google Patents

Composicion farmaceutica que comprende un betabloqueante y un inhibidor de la enzima de conversion.

Info

Publication number
MX2017005848A
MX2017005848A MX2017005848A MX2017005848A MX2017005848A MX 2017005848 A MX2017005848 A MX 2017005848A MX 2017005848 A MX2017005848 A MX 2017005848A MX 2017005848 A MX2017005848 A MX 2017005848A MX 2017005848 A MX2017005848 A MX 2017005848A
Authority
MX
Mexico
Prior art keywords
bisoprolol
pharmaceutical composition
perindoril
composition
perindopril
Prior art date
Application number
MX2017005848A
Other languages
English (en)
Inventor
Fonknechten Gilles
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52345359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005848(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2017005848A publication Critical patent/MX2017005848A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica fija que comprende un betabloqueante, bisoprolol, y un inhibidor de la enzima de conversión de la angiotensina, perindropil y, utilización de dicha composición para el tratamiento y la prevención de enfermedades cardiovasculares y más particularmente hipertensión arterial, enfermedad coronaria estable o insuficiencia cardiaca crónica.
MX2017005848A 2014-11-05 2015-11-04 Composicion farmaceutica que comprende un betabloqueante y un inhibidor de la enzima de conversion. MX2017005848A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1460654A FR3027803B1 (fr) 2014-11-05 2014-11-05 Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion
PCT/FR2015/052975 WO2016071631A1 (fr) 2014-11-05 2015-11-04 Composition pharmaceutique comprenant le bisoprolol et le périndopril

Publications (1)

Publication Number Publication Date
MX2017005848A true MX2017005848A (es) 2017-06-27

Family

ID=52345359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005848A MX2017005848A (es) 2014-11-05 2015-11-04 Composicion farmaceutica que comprende un betabloqueante y un inhibidor de la enzima de conversion.

Country Status (24)

Country Link
EP (1) EP3215130B1 (es)
CY (1) CY1123322T1 (es)
DK (1) DK3215130T3 (es)
EA (1) EA032808B1 (es)
ES (1) ES2811904T3 (es)
FR (1) FR3027803B1 (es)
GE (1) GEP20196989B (es)
HR (1) HRP20201518T1 (es)
HU (1) HUE051947T2 (es)
LT (1) LT3215130T (es)
MA (1) MA40915B1 (es)
MX (1) MX2017005848A (es)
MY (1) MY187357A (es)
PH (1) PH12017500786A1 (es)
PL (1) PL3215130T3 (es)
PT (1) PT3215130T (es)
RS (1) RS60657B1 (es)
RU (1) RU2702362C2 (es)
SG (2) SG10201903656RA (es)
SI (1) SI3215130T1 (es)
TN (1) TN2017000170A1 (es)
UA (1) UA122131C2 (es)
WO (1) WO2016071631A1 (es)
ZA (1) ZA201703078B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3234743A1 (en) 2021-10-20 2023-04-27 Les Laboratoires Servier Novel trimetazidine salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137054A1 (en) 2002-05-03 2004-07-15 Alexandra Hager Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors
WO2007010501A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
NZ596064A (en) * 2009-04-30 2014-03-28 Reddy’S Lab Ltd Dr Fixed dose drug combination formulations
EA201691986A1 (ru) 2010-05-06 2017-03-31 СиЭйЭл ИНТЕРНЕШНЛ ЛИМИТЕД Фармацевтическая композиция, содержащая аспирин и бисопролол

Also Published As

Publication number Publication date
MY187357A (en) 2021-09-22
ES2811904T3 (es) 2021-03-15
FR3027803B1 (fr) 2018-02-09
MA40915B1 (fr) 2020-08-31
LT3215130T (lt) 2020-08-25
HRP20201518T1 (hr) 2020-12-11
PT3215130T (pt) 2020-08-26
HUE051947T2 (hu) 2021-03-29
EA201790772A1 (ru) 2017-09-29
RS60657B1 (sr) 2020-09-30
RU2702362C2 (ru) 2019-10-08
SG11201703550SA (en) 2017-06-29
SG10201903656RA (en) 2019-05-30
PH12017500786B1 (en) 2017-10-02
UA122131C2 (uk) 2020-09-25
DK3215130T3 (da) 2020-09-21
EP3215130B1 (fr) 2020-07-08
TN2017000170A1 (fr) 2018-10-19
ZA201703078B (en) 2020-11-25
SI3215130T1 (sl) 2020-11-30
PH12017500786A1 (en) 2017-10-02
FR3027803A1 (fr) 2016-05-06
RU2017115341A3 (es) 2019-05-21
PL3215130T3 (pl) 2020-11-16
WO2016071631A1 (fr) 2016-05-12
GEP20196989B (en) 2019-07-10
EA032808B1 (ru) 2019-07-31
RU2017115341A (ru) 2018-11-05
EP3215130A1 (fr) 2017-09-13
CY1123322T1 (el) 2021-12-31

Similar Documents

Publication Publication Date Title
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
EA201692436A1 (ru) Медицинское применение
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
WO2013177535A3 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
EA201790590A1 (ru) Гуманизированное моноклональное антитело, ингибирующее ферментативную активность сосудисто-эндотелиальной липазы
WO2015179823A8 (en) Lung localized inhibitors of alpha(v)beta 6
MX2021000133A (es) Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa.
EA201692202A1 (ru) Способы лечения сердечно-сосудистых заболеваний
CY1123322T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα μπισοπρολολη και περινδροπριλη
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
RU2011108668A (ru) Штамм aspergillus ochraceus wilhelm продуцент протеиназы-активатора протеина с плазмы крови
GB2549031A (en) Methods and drug therapies for patency of occluded blood vessels following angioplasty
TN2018000344A1 (en) Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
CO2019005207A2 (es) Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética
MX2019014773A (es) Inhibidores de ccl2.
TH173740B (th) สไพโรไซโคลเฮพเทนเป็นสารยับยั้งของ rock
EA202191138A1 (ru) Композиции и способы для ингибирования активности аргиназы
EA202091668A3 (ru) Ингибиторы калликреина плазмы человека
TH167869A (th) สารยับยั้ง ido

Legal Events

Date Code Title Description
FG Grant or registration